EGFR and neoplasm: However, challenging data haverecently been demonstrated that the primary tumor test at a single site insynchronic metastatic colorectal disease can result in an incomplete profile of theKRAS mutation and, consequently, an incorrect choice of the use of EGFR inhibitorsas treatment.10